title: Oncologists push beyond new lung cancer genomic testing guidelines.
authors: Ken
authors: K
authors: Garber
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077547:Crizotinib; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D005820:Genetic Testing / Q000592:standards*; D023281:Genomics; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D008495:Medical Oncology; D058990:Molecular Targeted Therapy / Q000379:methods; D009154:Mutation; D017410:Practice Guidelines as Topic / Q000592:standards; D057285:Precision Medicine; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D012955:Societies, Medical; D013450:Sulfones / Q000627:therapeutic use; D014178:Translocation, Genetic
chemical_list: D000970:Antineoplastic Agents; D011720:Pyrazoles; D011725:Pyridines; D011743:Pyrimidines; D011799:Quinazolines; D013450:Sulfones; D000077547:Crizotinib; D000069347:Erlotinib Hydrochloride; D000077548:Anaplastic Lymphoma Kinase; C512478:EGFR protein, human; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases; C586847:ceritinib; D000077156:Gefitinib